Exchange: OTC·Updated 01:09 PM EDT

NKGN NKGen Biotech Inc

$0.0111
$0.00
(0.00%)
Today
Mkt Cap$1.45M
Vol5,185.00

About NKGN

NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.
50

Neutral Sentiment

How do you feel about NKGN?

GoldGhost
$NKGN This is the reason behind the focus on the Asian markets. Fingers crossed he has made the right decision.
5
BCINU
$NKGN I averaged down before it was taken off of NASDAQ and now have over 100,000 shares at 24 cents. I am hoping for a big payday one day or I get screwed like the rest of us
4
GoldGhost
$NKGN “Enjoying a glorious day in Tokyo with and the Heka Bio team who are working with to bring our NK cell therapy (troculeucel) to the Japanese market. Under Japan's Yokohama declaration for regenerative medicine, we will soon begin commercial sales and treatment pending official inspections of our Korea and U.S. GMP facilities by the Japanese regulatory authorities. Our goal is to launch later this year.” -Paul Song July 8th, 2026
2
BCINU
$NKGN Chairman Paul Song made an interesting comment on LinkedIn on funding and commitment throughout Asia and Hong Kong.
2
RupertDCat
$NKGN Hope the presentation next week doesn’t just recycle old information, need to get some insight as to what the plan is going forward, especially with shares locked in expert market purgatory. Here is a snapshot from the press release. Dr. Song’s presentation will discuss the use of troculeucel in neurodegenerative diseases, including troculeucel’s mechanism of action in reducing cerebrospinal fluid (“CSF”) neuroinflammatory and protein biomarkers, clinical experience with troculeucel in patients with Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”), and frontotemporal dementia (“FTD”), and the regulatory landscape in Asia that may help expedite the development and commercialization of troculeucel.
2
whereisthebull50
$NKGN I have one qq. Why they are not putting much effort to list at least on OTC market. With all those news and progress they made I am pretty sure it would be trading at much higher prices. They can easily raise money instead of giving away stocks and million of warrants frequently @.08. Anybody?
1
whereisthebull50
$NKGN The Liar CEO arranged one more China seminar. According to his commitment and agreement, HekaBio was supposed to start trial in japan by July 2026. Is it a very high profile AD scam going on? Hope it's not. I bouhgt at high price. Now we can't even buy to average down and they are running the dilution machine continuosy. Too much money lost.
1
Picklerinthekitchen
$NKGN nothing here to see on this stock , soon it will probably just disappear off any exchange left.
1
whereisthebull50
$NKGN Question is why he is trying to go to Asian/Japan market now. Even though Phase 2 was started on US almost 3 years back. Is he finding any difficulties with FDA alignment. Anybody?
1
Picklerinthekitchen
$NKGN CEO speaking on old data news and nobody can buy stock in on pink sheets exchange , what a waste but collecting a nice salary I’m sure.

Advertisement|Remove ads.